Want to see KURA full AI Analyst Report?
KURA Stock Chart & Stats
$13.59
-$0.06(-0.57%)
At close: 4:00 PM EDT
$13.59
-$0.06(-0.57%)
Day’s Range― - ―
52-Week Range$7.36 - $13.90
Previous CloseN/A
Volume1.14M
Average Volume (3M)1.98M
Market Cap
$947.43M
Enterprise Value$480.17M
Total Cash (Recent Filing)$519.02M
Total Debt (Recent Filing)$24.45M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Oct 29, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.37
Shares Outstanding88,960,620
10 Day Avg. Volume1,893,703
30 Day Avg. Volume1,975,113
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)5.23
Price to Sales (P/S)13.50
P/FCF Ratio-12.89
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue6.22
Enterprise Value/Gross Profit6.56
Enterprise Value/Ebitda-1.64
Forecast
1Y Price Target
$26.81Price Target Upside97.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.22
Revenue Forecast (FY)$96.58M
Bulls Say, Bears Say
Bulls Say
Early COMZIFTI Commercial Traction And Market AccessCOMZIFTI is showing meaningful early adoption, with rapid growth in new starts and prescriptions and majority share of new patient starts in its targeted AML setting. Broad payer coverage and preferred status can support continued physician access and provide a foundation for durable commercial expansion.
Promising Precision-oncology Clinical PipelineThe pipeline is supported by clinically meaningful signals across genetically defined cancers and multiple combination strategies. Strong response data and ongoing pivotal development could expand Kura’s addressable opportunities, strengthen its competitive position, and support future product-line durability.
Funding Support For Pivotal Ziftomenib DevelopmentThe stated funding plan gives Kura a defined runway toward an important Phase 3 readout, reducing immediate pressure to interrupt development or seek capital solely to reach that milestone. Maintained collaboration guidance and anticipated partner payments add support to near-term execution.
Bears Say
Large Continuing Operating And Net LossesKura’s commercial launch has not yet translated into sustainable profitability because operating expenses remain far above the current revenue base. Continued large losses can consume capital for several periods, constrain investment flexibility, and increase the importance of successful product and pipeline execution.
Persistent Cash Burn And Rising Financing RiskNegative operating and free cash flow indicate that Kura is still funding its activities from existing resources and external capital rather than internally generated cash. The substantial decline in liquidity raises the risk of future financing needs, potential dilution, or reduced flexibility if development spending continues.
Long-dated Clinical Milestones And Execution UncertaintyImportant clinical value inflection points remain years away, leaving the business exposed to development, timing, and outcome risk before pivotal evidence is available. The duration of patient benefit and real-world outcomes are also not yet established, increasing uncertainty around eventual adoption and expansion.
Kura Oncology News
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $7.36 and its highest was $13.90 in the past 12 months.
What is Kura Oncology’s market cap?
Kura Oncology’s market cap is $947.43M.
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Oct 29, 2026 which is in 23 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Aug 12, 2026. The company reported -$0.77 earnings per share for the quarter, beating the consensus estimate of -$0.877 by $0.107.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -0.81.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 88,960,620 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -$0.77 in its last earnings report, beating expectations of -$0.877. Following the earnings report the stock price went up 1.509%.
Which hedge fund is a major shareholder of Kura Oncology?
Currently, no hedge funds are holding shares in KURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kura Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.81 (97.31% Upside)
$26.81 (97.31% Upside)
Blogger Sentiment
Bullish
KURA Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 560.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kura Oncology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
KURA Company Deck
KURA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong early commercial traction for COMZIFTI (notable revenue, majority share of new patient starts, high Q/Q growth in starts and prescriptions), robust clinical data across Ziftomenib and promising darlifarnib combination signals in multiple solid tumor settings. Financials show solid funding runway with Kyowa Kirin support but also reflect increased commercial spend, a declining cash balance since year‑end, and a YoY decline in collaboration revenue. Competitive noise around market share and the multi‑year timelines to pivotal readouts add uncertainty. Overall, positive operational and clinical momentum is balanced against near‑term financial and competitive considerations.View all KURA earnings summariesKURA Stock 12 Month Forecast
Average Price Target
$26.81
▲(97.31% Upside)
Technical Analysis
Geron
―
CytomX Therapeutics
―
Zentalis Pharmaceuticals
―
Oric Pharmaceuticals
―
Prelude Therapeutics
―
Ownership Overview
2.45% Insiders
10.74% Mutual Funds
40.99% Other Institutional Investors
29.23% Public Companies and Individual Investors